©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 14, 2017; 23(30): 5469-5485
Published online Aug 14, 2017. doi: 10.3748/wjg.v23.i30.5469
Published online Aug 14, 2017. doi: 10.3748/wjg.v23.i30.5469
Treating children with inflammatory bowel disease: Current and new perspectives
Graziella Guariso, University of Padova, 35100 Padova, Italy
Marco Gasparetto, Department of Paediatric Gastroenterology, Cambridge University Hospitals CUH-FT, Cambridge CB2 0QQ, United Kingdom
Author contributions: Guariso G and Gasparetto M contributed equally to this work in respect to designing the review, contributing to the manuscript with intellectual content, writing the paper and final approval of the version to be published.
Conflict-of-interest statement: No potential conflicts of interest. No financial support.
Correspondence to: Graziella Guariso, Professor, Paediatric Gastroenterologist, University Lecturer, University of Padova, Via 8 Febbraio 1848, 2, 35100 Padova, Italy. graziella.guariso@gmail.com
Telephone: +39-49-8625753 Fax: +39-49-8625753
Received: February 26, 2017
Peer-review started: February 28, 2017
First decision: April 7, 2017
Revised: June 2, 2017
Accepted: July 22, 2017
Article in press: July 24, 2017
Published online: August 14, 2017
Processing time: 168 Days and 22.9 Hours
Peer-review started: February 28, 2017
First decision: April 7, 2017
Revised: June 2, 2017
Accepted: July 22, 2017
Article in press: July 24, 2017
Published online: August 14, 2017
Processing time: 168 Days and 22.9 Hours
Core Tip
Core tip: This narrative review summarises the current practice in treating children with inflammatory bowel disease (IBD) and explores the new advances and future aims. A particular focus of the review are the peculiarities of the paediatric age in respect to the standard practice in adult patients with IBD. Whilst the cause of this condition remains only partly understood, a significant proportion of children does not respond to the treatment options currently available. Developing new treatments is therefore a key target. Major advances have already been achieved in therapeutic drug monitoring.